Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04983745
Title Niraparib and Dostarlimab in HRD Solid Tumors (DIDO)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors West Cancer Center
Indications

Advanced Solid Tumor

Therapies

Dostarlimab-gxly + Niraparib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST